Advertisement
Advertisement
IBO
Impact BioMedical, Inc.
4.62
USDSponsored
+0.29
+6.70%
Nov 10, 15:59 UTC -5
Closed
After-Market
4.76
+0.14
+3.03%
Impact BioMedical, Inc. (IBO) Earnings
IBO Earnings Reports
Positive Surprise Ratio
No Data Available for IBO
0%
Next Report
Date of Next Report
Mar 11, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Impact BioMedical, Inc. earnings per share and revenue
On Nov 09, 2026, IBO reported earnings of -0.08 USD per share (EPS) for Q3 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached 20.00 thousand, compared to an expected --, with a --% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
CalciMedica, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.30
Actual
-$0.72
Surprise
+44.64%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
FAQ
What were Impact BioMedical, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Impact BioMedical, Inc. reported EPS of -$0.08, missing estimates by --, and revenue of $20.00K, -- -- expectations.
How did the market react to Impact BioMedical, Inc.'s Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Impact BioMedical, Inc. expected to report next?
The next earning report is scheduled for Mar 11, 2027.
What are the forecasts for Impact BioMedical, Inc.'s next earnings report?
Based on --
analysts, Impact BioMedical, Inc. is expected to report EPS of -- and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.